SEC Form 4 · accession 0001144204-18-015633
ANI PHARMACEUTICALS INC · ANIP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Raynor
Director
Period of report
Mar 15, 2018
Accepted (ET)
Mar 19, 2018 · 4:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001023024
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 15, 2018 | S | 1,902 | $61.50 | D | 294,316 | I | See Footnote |
| Common StockF3,F2 | Mar 19, 2018 | S | 5,313 | $60.62 | D | 289,003 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $61.00 to $62.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1).
- F3This transaction was executed in multiple trades at prices ranging from $60.50 to $60.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.